id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-265751-q1ecpfyg	Shahani, Lokesh	Antiviral therapy for respiratory viral infections in immunocompromised patients	2017-01-16		.txt	text/plain	10657	523	34	� High prevalence of M2 inhibitors resistance detected in influenza A (H3N2) and 2009 H1N1 virus strains preclude their use for prophylaxis or empiric treatment of seasonal influenza � Neuraminidase inhibitors are the first line agents for treatment of Influenza and treatment is most likely to provide the most benefit when initiated within the first 48 h of illness � Zanamivir is currently the therapy of choice for the treatment of oseltamivir-resistant influenza infection � An immunodeficiency scoring index for RSV, that accounts for the number of risk factors, can be used to identify HSCT recipients who are at high risk for progression to RSV LRTI and RSV associated mortality � Ribavirin-based therapy (alone or in combination with immunomodulators) can be effective in preventing progression from URTI to LRTI and may improve mortality in highly immunosuppressed adult HSCT recipients � The safety and efficacy of DAS181 in immunocompromised patients with PIV pneumonia, is currently being studied in an ongoing phase 2 double-blind, placebo-controlled trial.	./cache/cord-265751-q1ecpfyg.txt	./txt/cord-265751-q1ecpfyg.txt